© Rosalind Scientific LLC 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > SAR439859
<< Back to December
oral sel. estrogen receptor degrader (SERD)
400 mg QD, in Ph. II for ER+/HER2- BC
from MTS of ER binders, opt. for degrd./antag.
Mol. Cancer Ther., Dec. 11, 2020
Sanofi, Vitry-sur-Seine, FR / Cambridge MA
Sanofi oral selective estrogen receptor (ER) degrader (SERD)
Unlock this content with a Premium membership to read it now.